The deal announced on Oct. 21, 2019 adds Danaher’s FortéBio, SoloHill and chromatography hardware and resins businesses, complementing Sartorius’s position in the fast-growing bioanalytics and bioprocessing sectors. The combined assets generated revenue of approximately $170 million last year.

Calling the acquisition of the portfolio a further milestone for Sartorius, executive board chairman and CEO Joachim Kreuzburg said the assets “are an excellent strategic and operational fit with both our divisions.” The purchase adds approximately 300 employees.

The FortéBio business for label-free biomolecular characterization includes innovative protein analysis instruments, biosensors and reagents that are used in drug discovery. The products are based on patented biolayer interferometry technology and perform real-time analysis of various biomolecular interactions.

Employing about 200 people worldwide, the production sites in Fremont, California, USA, and Shanghai, China, will be integrated into the bioanalytics unit within the Sartorius Lab Products & Services Division.

SoloHill, which comprises microcarrier technology and particle validation standards used in cell cultures and other bioprocesses, and Danaher’s chromatography systems and resins business will both become part of Sartorius’s bioprocess solutions division.

Together, these businesses employ some 100 people at sites in Portsmouth, UK, Cergy, France, Ann Arbor, Michigan, USA, and Hopkinton, Massachusetts, USA.